Conversations Contributors - Kenneth A. Getz

Mr. Getz is an internationally recognized expert on R&D and clinical trial management practices and trends, the global investigative site landscape, site management and patient recruitment and retention practices, and the worldwide market for outsourcing clinical research functions.  Mr.

Conversations Contributors - Rebecca Li

Rebecca Li has over 17 years of experience spanning the entire drug development process with experience in Biotech, Pharma and CRO environments. Dr. Li currently serves as the Executive Director of the MRCT Center at Harvard. The Center was chartered to improve the design, conduct and oversight of multi-regional clinical trials in the developing world and simplifying research through best practices. Prior to joining the MRCT Center, Dr.

Conversations Contributors - Peter Pitts

Peter Pitts is President and co-founder of the Center for Medicine in the Public Interest. Prior to founding CMPI, Pitts was a Senior Fellow for healthcare studies at the Pacific Research Institute. From 2002-2004 Peter was FDA’s Associate Commissioner for External Relations, serving as senior communications and policy adviser to the Commissioner.

Conversations Contributors - Stevin Zorn

Stevin Zorn is Executive Vice President and US site head for Neuroscience Research at Lundbeck Research USA since 2008. He is a member of Lundbeck's Global Research Leadership Team, Development Committee, R&D Management group, and the R&D Executive Committee.


How do we balance the public health benefit of sharing clinical study information with the need to respect patient privacy and encourage continued innovation?

Contributors Respond

Conversations: What can be done to generate more innovations from public-private partnerships?

08.01.13 | By

Biomedical research is behind the scientific advances that have helped increase the childhood cancer survivor rate and improve and lengthen the lives of people living with HIV/AIDs, heart disease and cancer. The next set of health care challenges to overcome include dementia and Alzheimer’s disease – neurological disorders that are on the rise and will have a major impact on our communities in the next 50 years.


How can we better utilize public-private partnerships to advance translation of science into new medicines for some of our most challenging diseases, such as neurological disorders?

Contributors Respond

Conversations Round-Up

07.30.13 | By

Every person is unique, and so are the challenges they face when it comes to their health. However, there are some core opportunities to improve care across wide swaths of the population, and that’s why we asked last week’s Conversations question: “What are the biggest challenges and opportunities when it comes to improving patient health?”

Conversations Contributors - Adam Gilden Tsai

Patient Challenges and Opportunities

07.23.13 | By

The United States faces a growing number of health care challenges. Rates of chronic disease continue to climb, and by 2020, more than half the country is expected to suffer from a condition such as obesity, diabetes or chronic obstructive pulmonary disease (COPD) by 2020.


Subscribe to RSS - conversations